What Does the Tysabri PML Warning Mean for North Carolina Patients?

From General Health Communication to Occupational and Legal Awareness

If you or a loved one is taking Tysabri for multiple sclerosis or Crohn's disease, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). The FDA has issued a boxed warning highlighting that PML can occur in patients treated with Tysabri, especially those with certain risk factors. Building on decades of medical research and regulatory oversight, this page provides a clear summary of what the warning means and how it applies to patients in North Carolina.

Tysabri and PML: Medical Evidence and Risk Factors

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn’s disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies three key risk factors for PML development: the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be weighed against expected benefit when initiating or continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by reactivation of the John Cunningham virus (JCV) in the brain, leading to progressive neurological deficits. Clinical presentation typically includes subacute onset of cognitive impairment, motor weakness, visual disturbances, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white-matter lesions and detection of JCV DNA in cerebrospinal fluid. The mechanistic link between Tysabri and PML involves the drug’s action as an alpha-4 integrin antagonist, which inhibits lymphocyte trafficking into the central nervous system. This immunosuppressive effect reduces immune surveillance, allowing JCV to replicate unchecked in oligodendrocytes. The FDA Adverse Event Reporting System (FAERS) data show that Tysabri is associated with frequent reports of neurological symptoms such as gait disturbance (9422 reports), memory impairment (7895 reports), balance disorder (5621 reports), and cognitive disorder (3478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm PML, they underscore the drug’s neurological adverse-effect profile.

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Tysabri and PML is a central issue for affected patients. The boxed warning explicitly states that Tysabri increases PML risk and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, with dosing withheld immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether prescribers adequately communicated the risk of PML, especially in patients who developed the condition after prolonged therapy. The duration of treatment prior to PML onset can range from a few months to several years, as noted for herpes infections in the same label (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variable timeline complicates attribution of harm and may affect legal considerations.

Statute of Limitations for Tysabri Claims in North Carolina

For patients in North Carolina who developed PML after Tysabri use, attorney-related considerations include the statute of limitations for filing a product-liability or medical-malpractice claim. In North Carolina, the statute of limitations for personal injury actions is generally three years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For PML, the date of discovery is often when a definitive diagnosis is made via MRI and CSF analysis. The timeline between Tysabri exposure and documented harm is critical: PML symptoms may emerge months to years after starting therapy, and the diagnosis may be delayed due to nonspecific early signs. Patients should consult with an attorney experienced in pharmaceutical litigation to determine whether their claim falls within the applicable limitations period. Evidence of inadequate warning—such as failure to discuss PML risk factors or to monitor for early symptoms—may strengthen a claim. The boxed warning and TOUCH program requirements provide a regulatory baseline, but individual circumstances may vary. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and a requirement for patient monitoring. The timeline from exposure to harm can be prolonged, and the adequacy of warnings is a key legal issue. North Carolina patients affected by PML should seek timely legal advice to preserve their rights under the statute of limitations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Time is limited. Request your evaluation today.

Do not fill

We connect historical research with modern accountability. Submitting this form does not immediately create an attorney-client relationship. Urgent medical issues require emergency services.

By clicking the button below, I expressly consent to be contacted by the operator of this website and one legal intake partner matched to my inquiry via phone calls, emails, and/or text messages at the number provided. I understand that this contact may include the use of an automated telephone dialing system (ATDS) or artificial/prerecorded voices. I acknowledge that my consent is not a condition of purchasing any goods or services, and I can revoke it at any time. See If I Qualify

​

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in North Carolina?

In North Carolina, the statute of limitations for personal injury actions is generally three years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For PML, the date of discovery is often when a definitive diagnosis is made via MRI and CSF analysis. Patients should consult with an attorney experienced in pharmaceutical litigation to determine whether their claim falls within the applicable limitations period.

What are the key risk factors for developing PML while on Tysabri?

The prescribing information identifies three key risk factors: the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be weighed against expected benefit when initiating or continuing treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Related Articles

• FDA warning Tysabri Progressive Multifocal Leukoencephalopathy
• Does Tysabri cause Progressive Multifocal Leukoencephalopathy

References

1. Tysabri Prescribing Information (DailyMed)
2. FDA Adverse Event Reporting System (FAERS) for Tysabri

Request a Free Case Review

Begin Assessment

Submitting requests an initial records screening only and does not create an attorney-client relationship.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.